Dr A. Michael Lincoff, MD, assumes the role of Vice Chairman within the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, acting as an interventional cardiologist at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.
With a purview extending beyond clinical practice, Dr Lincoff spearheads clinical research endeavours throughout the Cleveland Clinic as the Director of the Center for Clinical Research at the Lerner Research Institute. He is also at the helm of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), an academic research organization dedicated to planning, coordinating, and managing multicenter clinical trials exploring new pharmacologic or device therapies.
Dr Lincoff's research endeavours are concentrated on advancing therapies aimed at mitigating acute and long-term complications of percutaneous coronary revascularization procedures. Additionally, his work seeks to optimize therapy for acute coronary ischemic syndromes and reduce the progression or complications of atherosclerosis. As a principal investigator or steering committee member, he has played pivotal roles in over 15 pivotal trials in ischemic heart disease, collectively enrolling over 50,000 patients. These trials focus on studying new antiplatelet or antithrombotic agents in the contexts of coronary intervention, heart attack, or unstable angina.
Academically, Dr. Lincoff holds the position of Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is also the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research at Cleveland Clinic.
Dr. Lincoff's extensive contributions to the scientific community are reflected in his authorship or co-authorship of over 200 peer-reviewed articles, spanning prestigious journals such as the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, Journal of the American College of Cardiology, American Heart Journal, and European Heart Journal. He serves as the editor of the book "Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease," currently in its second edition, and has authored over 80 book chapters and reviews. An experienced speaker, Dr. Lincoff has presented over 300 lectures at medical meetings and courses worldwide.
His editorial roles include being the Consulting Editor of the American Journal of Cardiovascular Drugs, along with serving on editorial boards or as a reviewer for over 15 peer-reviewed scientific journals. Currently, Dr. Lincoff holds the position of chairman of the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration.
Dr. Lincoff's professional affiliations include being a fellow of the American College of Cardiology and the European Society of Cardiology and a member of the American College of Physicians, scientific councils of the American Heart Association, and the Sigma Xi Scientific Research Society.
